Stem Cell Innovations officially opened its european R&D facility in Leiden, the Netherlands
Stem Cell Innovations, Inc. has opened a new R&D facility to commercialise their proprietary platform of human pluripotent stem cells (PCs(TM)) in Europe. The facility is based in Leiden, the Netherlands and encompasses 1,000 m2 of state-of-the-art research laboratories.
"Establishing a site in Europe is part of SCIZs strategy to become a global leading player in the rapidly evolving stem cell field", said CEO Dr. James Kelly. "We are now in a much better position to efficiently serve the growing European market for high quality drug discovery tools, including complex disease models that can be alternatives for animal testing. Moreover a site in the Netherlands will allow high-level interactions with EU leaders in cell-therapeutics, both from Industry and Academia".
The Company recently disclosed it has produced multiple lines of human pluripotent stem cells. These PC lines are able to maintain their undifferentiated state and normal chromosome complement. More importantly, the cells can be efficiently cultured in tissue culture plates without the use of feeder layers (xenofree).
The European site of SCI will be led by Dr. Helmuth van Es (CSO) and Ivo Piest (Senior Director Business & Corporate Development), both members of the Company's global management team.
Other news from the department science
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
